Healthcare provider profile · identity verified

Eileen Boyle, MD

Internal Medicine · ELLWOOD CITY, PA · NPI 1336162023

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	416	117
Lisinopril	Lisinopril	345	95
Levothyroxine Sodium	Levothyroxine Sodium	274	79
Amlodipine Besylate	Amlodipine Besylate	242	65
Gabapentin	Gabapentin	240	63
Omeprazole	Omeprazole	213	60
Losartan Potassium	Losartan Potassium	186	60
Eliquis	Apixaban	180	38
Simvastatin	Simvastatin	168	51
Pantoprazole Sodium	Pantoprazole Sodium	165	54
Rosuvastatin Calcium	Rosuvastatin Calcium	161	52
Metoprolol Tartrate	Metoprolol Tartrate	142	41
Metformin Hcl	Metformin Hcl	133	40
Sertraline Hcl	Sertraline Hcl	125	34
Furosemide	Furosemide	121	39
Metoprolol Succinate	Metoprolol Succinate	119	40
Albuterol Sulfate Hfa	Albuterol Sulfate	115	33
Alendronate Sodium	Alendronate Sodium	104	30
Ozempic	Semaglutide	100	13
Escitalopram Oxalate	Escitalopram Oxalate	91	21
Glipizide Er	Glipizide	79	17
Montelukast Sodium	Montelukast Sodium	75	17
Meloxicam	Meloxicam	71	26
Famotidine	Famotidine	69	27
Hydrochlorothiazide	Hydrochlorothiazide	68	21
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	68	23
Jardiance	Empagliflozin	61	17
Glipizide	Glipizide	57	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	56	12
Duloxetine Hcl	Duloxetine Hcl	53	14
Potassium Chloride	Potassium Chloride	53	18
Pravastatin Sodium	Pravastatin Sodium	53	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	51	suppressed
Warfarin Sodium	Warfarin Sodium	50	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	48	13
Atenolol	Atenolol	46	15
Clopidogrel	Clopidogrel Bisulfate	46	14
Allopurinol	Allopurinol	45	13
Alprazolam	Alprazolam	45	22
Citalopram Hbr	Citalopram Hydrobromide	44	12
Ibuprofen	Ibuprofen	43	12
Celecoxib	Celecoxib	42	12
Lansoprazole	Lansoprazole	41	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	41	12
Prednisone	Prednisone	40	17
Xarelto	Rivaroxaban	40	suppressed
Benazepril Hcl	Benazepril Hcl	38	suppressed
Synthroid	Levothyroxine Sodium	38	13
Fluticasone Propionate	Fluticasone Propionate	37	14
Bupropion Hcl Sr	Bupropion Hcl	36	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	36	14
Ezetimibe	Ezetimibe	36	suppressed
Trazodone Hcl	Trazodone Hcl	36	12
Carvedilol	Carvedilol	33	suppressed
Donepezil Hcl	Donepezil Hcl	32	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	30	suppressed
Paroxetine Hcl	Paroxetine Hcl	30	suppressed
Tramadol Hcl	Tramadol Hcl	30	17
Hydralazine Hcl	Hydralazine Hcl	29	11
Olmesartan Medoxomil	Olmesartan Medoxomil	29	suppressed
Buspirone Hcl	Buspirone Hcl	27	suppressed
Metformin Hcl Er	Metformin Hcl	27	suppressed
Naproxen	Naproxen	27	suppressed
Ropinirole Hcl	Ropinirole Hcl	27	suppressed
Humalog Kwikpen U-100	Insulin Lispro	26	suppressed
Valsartan	Valsartan	26	suppressed
Bumetanide	Bumetanide	25	suppressed
Azelastine Hcl	Azelastine Hcl	24	suppressed
Diclofenac Sodium	Diclofenac Sodium	24	suppressed
Rybelsus	Semaglutide	24	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	23	suppressed
Chlorthalidone	Chlorthalidone	22	suppressed
Ondansetron Hcl	Ondansetron Hcl	22	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	22	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	20	suppressed
Meclizine Hcl	Meclizine Hcl	20	13
Valacyclovir	Valacyclovir Hcl	20	suppressed
Azithromycin	Azithromycin	19	14
Clonidine Hcl	Clonidine Hcl	19	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	19	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	18	14
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	18	suppressed
Cholestyramine	Cholestyramine (With Sugar)	17	suppressed
Mupirocin	Mupirocin	17	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Primidone	Primidone	16	suppressed
Trulicity	Dulaglutide	16	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Latanoprost	Latanoprost	14	suppressed
Lorazepam	Lorazepam	14	suppressed
Methylprednisolone	Methylprednisolone	14	13
Amantadine	Amantadine Hcl	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Jantoven	Warfarin Sodium	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	11
Sotalol	Sotalol Hcl	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Klor-Con M20	Potassium Chloride	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Arnuity Ellipta	Fluticasone Furoate	11	suppressed
Baclofen	Baclofen	11	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	11	suppressed
Finasteride	Finasteride	11	suppressed
Folic Acid	Folic Acid	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Novolog Flexpen	Insulin Aspart	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Rizatriptan	Rizatriptan Benzoate	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error